ARS Pharmaceuticals (SPRY) Equity Ratio (2021 - 2025)
Historic Equity Ratio for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to 0.4.
- ARS Pharmaceuticals' Equity Ratio fell 5711.74% to 0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4, marking a year-over-year decrease of 5711.74%. This contributed to the annual value of 0.73 for FY2024, which is 2610.06% down from last year.
- According to the latest figures from Q3 2025, ARS Pharmaceuticals' Equity Ratio is 0.4, which was down 5711.74% from 0.61 recorded in Q2 2025.
- ARS Pharmaceuticals' 5-year Equity Ratio high stood at 0.99 for Q4 2023, and its period low was 0.51 during Q4 2021.
- Moreover, its 5-year median value for Equity Ratio was 0.95 (2021), whereas its average is 0.81.
- Its Equity Ratio has fluctuated over the past 5 years, first surged by 29053.85% in 2022, then crashed by 5711.74% in 2025.
- Quarter analysis of 5 years shows ARS Pharmaceuticals' Equity Ratio stood at 0.51 in 2021, then skyrocketed by 290.54% to 0.97 in 2022, then rose by 2.06% to 0.99 in 2023, then fell by 26.1% to 0.73 in 2024, then crashed by 45.84% to 0.4 in 2025.
- Its last three reported values are 0.4 in Q3 2025, 0.61 for Q2 2025, and 0.7 during Q1 2025.